Aubagio® is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).
Rapid Review
| Commenced | Completed | Outcome |
| 27/08/2013 | 20/09/2013 | Full Pharmacoeconomic Evaluation recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 25/11/2013 | 19/06/2014 | Reimbursement Not Recommended |
The NCPE does not recommend reimbursement of teriflunomide (Aubagio®) at the current price.
05/09/2014
The HSE has approved reimbursement following confidential price negotiations.